Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $36.60

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given an average rating of “Buy” by the six research firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $37.17.

A number of research firms have recently weighed in on KNSA. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price target on the stock.

Kiniksa Pharmaceuticals Stock Up 1.6 %

KNSA stock opened at $22.97 on Thursday. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15. The stock’s 50 day moving average is $20.05 and its 200-day moving average is $22.10. The firm has a market capitalization of $1.67 billion, a PE ratio of -164.06 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the prior year, the business earned $0.35 EPS. The firm’s revenue for the quarter was up 46.9% compared to the same quarter last year. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Michael R. Megna sold 9,051 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at $595,553.60. This represents a 25.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,423 shares of company stock worth $1,541,812. 54.57% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds have recently made changes to their positions in KNSA. Los Angeles Capital Management LLC grew its position in shares of Kiniksa Pharmaceuticals by 26.3% in the third quarter. Los Angeles Capital Management LLC now owns 100,001 shares of the company’s stock valued at $2,499,000 after purchasing an additional 20,801 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at $268,000. Segall Bryant & Hamill LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at $675,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Kiniksa Pharmaceuticals by 40.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock valued at $8,098,000 after purchasing an additional 92,985 shares in the last quarter. Finally, Cerity Partners LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at $834,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.